Strengthens global intellectual property portfolio supporting the Company's novel cancer therapeutics
London, UK, 27 May 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for the Company's patent application titled "Piperazine Derivatives, Pharmaceutical Compositions and Methods of Use Thereof."
The allowed patent relates to proprietary piperazine derivatives, pharmaceutical compositions, and methods of use associated with Vidac Pharma's oncology therapeutic platform and represents an important addition to the Company's growing international intellectual property estate protecting its innovative cancer treatment technologies.
Dr. Max Herzberg, Chief Executive Officer of Vidac Pharma, commented: "The allowance of this patent application in Canada further strengthens Vidac Pharma's intellectual property position in an important international market. Expanding and protecting our patent portfolio remains a key strategic priority as we continue advancing our oncology and onco-dermatology development programmes and pursuing long-term commercial opportunities globally."
The Company continues to actively expand its patent portfolio worldwide in support of its development pipeline and proprietary technologies targeting cancer metabolism and the tumor microenvironment.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws.
For more information, please contact: Vidac Pharma Holdings Plc, Dr. Max Herzberg, 20-22 Wenlock Road, London N1 7GU, United Kingdom, investors@vidacpharma.com
About Vidac Pharma: Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines for oncologic and onco-dermatologic diseases.